Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite-Reference-Cited by-同舟云学术

Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite

Published:2020-05-06 Issue:542 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Albulescu Laura-Oana¹^ORCID,Hale Melissa S.¹^ORCID,Ainsworth Stuart¹^ORCID,Alsolaiss Jaffer¹,Crittenden Edouard¹^ORCID,Calvete Juan J.²^ORCID,Evans Chloe¹^ORCID,Wilkinson Mark C.¹,Harrison Robert A.¹³^ORCID,Kool Jeroen⁴,Casewell Nicholas R.¹³^ORCID

Affiliation:

1. Centre for Snakebite Research and Interventions, Liverpool School of Tropical Medicine, Pembroke Place, L3 5QA Liverpool, UK.

2. Laboratorio de Venómica Estructural y Funcional, Instituto de Biomedicina de Valencia, CSIC, Valencia 46010, Spain.

3. Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Pembroke Place, L3 5QA Liverpool, UK.

4. Amsterdam Institute for Molecules Medicines and Systems, Division of BioAnalytical Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, Netherlands.

Abstract

DMPS, a drug licensed to treat mercury poisoning, is preclinically effective as an oral therapeutic for treating certain hemotoxic snakebites.

Funder

Wellcome

Medical Research Council

Royal Society

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference61 articles.

1. Snakebite envenoming